Scott Medberry
unread,May 4, 2010, 12:35:35 PM5/4/10Sign in to reply to author
Sign in to forward
You do not have permission to delete messages in this group
Either email addresses are anonymous for this group or you need the view member email addresses permission to view the original message
to The Bottom Line Forum: Best Practices for Addressing Health Care Reform in Life Sciences
I would think that the smoothing methodologies will continue to be a
part of CMS guidance. The reasons for their use remain, including the
stabilization of AMP values between periods and the reduction of
impact if AMP is not restated due to additional lagged data becoming
available. The case could be argued that smoothing becomes even more
important now with HCR since presumably fewer transactions will be
included AMP in the retail community pharmacy class of trade, giving
any small change in the number or value of lagged discounts a
disproportionately larger change in the calculated AMP value unless
smoothing is used. Of course, CMS might have different ideas.